# Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)

> **NCT04560881** · PHASE3 · COMPLETED · sponsor: **Laboratorio Elea Phoenix S.A.** · enrollment: 3000 (actual)

## Conditions studied

- COVID-19 Virus Infection

## Interventions

- **BIOLOGICAL:** Inactivated SARS-CoV-2 vaccine (Vero cell)
- **BIOLOGICAL:** Placebo/Aluminum Adjuvant of Inactivated SARS-CoV-2 vaccine

## Key facts

- **NCT ID:** NCT04560881
- **Lead sponsor:** Laboratorio Elea Phoenix S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-16
- **Primary completion:** 2021-12-13
- **Final completion:** 2021-12-13
- **Target enrollment:** 3000 (ACTUAL)
- **Last updated:** 2022-01-12

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04560881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04560881, "Clinical Trial to Evaluate the Efficacy, Immunogenicity and Safety of the Inactivated SARS-CoV-2 Vaccine (COVID-19)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04560881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*